| Name | Title | Contact Details |
|---|---|---|
Kevin Dushney |
Vice President of Technology | Profile |
Vic Myer |
Chief Technology Officer | Profile |
Covance the development services company is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NGM Bio is a research-driven, clinical-stage biopharmaceutical company with a passion to improve the lives of those struggling with serious diseases. Our expertise in drug discovery and translational development, coupled with the significant resources from our partnership with Merck, is driving development of transformational medicines that dramatically improve human health. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio`s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles.
Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.
Pionyr Immuntherapeutics (formerly Precision Immune Inc.) is developing cancer immunotherapies that target the tumor microenvironment to enhance the body`s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company`s approach, Myeloid Tuning™, is designed to enhance the immune system`s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.
The IMV Technologies Group is a leader in the areas of animal and human assisted reproduction technologies and veterinary imaging. IMV Technologies provides customers with solutions for animal artificial insemination; its human division, Cryo Bio System, offers solutions for human assisted reproduction including human embryo vitrification, human sperm freezing and preservation and other assisted reproduction technologies. The IMV imaging business provides customers with veterinary imaging solutions.